文献速递药物不良反应与药物警戒特殊人群用药

GLP-1受体激动剂与肌肉骨骼结局:系统综述与荟萃分析

GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.
PubMed 文献 · Drugs · 2026-09-12

该系统综述与荟萃分析检索MEDLINE、CENTRAL与Embase至2025年3月,纳入60篇文章(46项随机对照试验、13项真实世界研究、1项药物警戒研究,共1,250,717人)。结果显示GLP-1受体激动剂对骨密度与骨折无显著影响,但瘦体重/去脂体重显著下降,关节WOMAC疼痛、功能与僵硬无显著变化,证据确定性低。

要点

  • GLP-1受体激动剂与瘦体重/去脂体重下降相关,效应主要由利拉鲁肽和司美格鲁肽驱动。
  • 骨密度(各部位)与骨折(各部位)在采用最充分校正效应量的模型中未见显著影响。
  • WOMAC疼痛、躯体功能与僵硬评分未见显著变化,肌肉功能与体能是否受损仍不确定。

核心结论

  • GLP-1受体激动剂对骨与关节结局无显著影响,但与瘦体重/去脂体重下降相关,证据确定性低,且变化似主要与体重下降有关。
  • 瘦体重/去脂体重下降在全局模型及所有敏感性分析中稳健,但能否转化为临床有意义的肌肉功能或体能损害尚不确定。

研究设计与样本

  • 系统综述与荟萃分析,检索MEDLINE、Cochrane CENTRAL与Embase自建库至2025年3月,并辅以手工检索。
  • 纳入随机对照试验或真实世界证据研究,共60篇文章:46项RCT、13项真实世界研究、1项药物警戒研究,合计1,250,717人。
  • 对至少2项研究报告的结局行随机效应模型荟萃分析,并按GLP-1受体激动剂种类、对照类型与研究设计行亚组分析。
  • 采用留一法敏感性分析及限定最充分校正效应估计的分析检验稳健性,并用GRADE评估证据强度,遵循PRISMA声明(PROSPERO CRD420251024082)。

主要发现

  • 从1148条潜在相关文献中纳入60篇文章,涵盖司美格鲁肽、利拉鲁肽、艾塞那肽、度拉糖肽、替尔泊肽(GIP/GLP-1双激动剂)等。
  • 骨结局(各部位骨密度与骨折)在荟萃模型纳入最充分校正效应量时未见显著影响。
  • 瘦体重/去脂体重显著下降:全局模型k=28,标准化均数差(SMD)0.52,95%置信区间(CI)-0.8至-0.23,I² 88%,异质性P值<0.0001。
  • 亚组分析显示该效应主要由利拉鲁肽与司美格鲁肽驱动,且在GLP-1受体激动剂与安慰剂比较时观察到瘦体重/去脂体重下降;未发现发表偏倚。
  • 关节结局方面,WOMAC疼痛、躯体功能与僵硬均未见显著变化。

关键数值与推荐

  • 瘦体重/去脂体重:k=28,SMD 0.52,95%CI -0.8至-0.23,I² 88%,异质性P<0.0001。
  • 骨密度(各部位)与骨折(各部位):采用最充分校正效应量的模型中无显著效应。
  • WOMAC疼痛、躯体功能与僵硬:无显著变化。
  • 证据确定性:GRADE评估为低。

临床怎么用

  • 对使用GLP-1受体激动剂的患者,尤其是利拉鲁肽与司美格鲁肽使用者,应关注瘦体重/去脂体重下降。
  • 目前证据不支持GLP-1受体激动剂对骨密度、骨折或关节WOMAC评分有显著不利影响,但证据确定性低。
  • 肌肉功能、肌力与体能是否受损尚不明确,临床需结合个体情况评估并等待进一步研究。

局限性

  • 纳入研究异质性较高(瘦体重/去脂体重分析I² 88%)。
  • 证据确定性经GRADE评估为低。
  • 缺乏肌肉功能、肌力或体能等结局,且需多变量模型校正混杂因素。
  • 瘦体重/去脂体重变化似主要与体重下降有关,其临床意义尚不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly used for the treatment of type 2 diabetes and obesity, but their effects on musculoskeletal health remain completely misunderstood. OBJECTIVE: This systematic review/meta-analysis aims to synthesise clinical data on the effects of GLP-1 RAs on key relevant bone, muscle, and joint outcomes. METHODS: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) (both via Ovid® platform) and Embase were searched from inception to March 2025 to identify relevant randomised controlled trials (RCTs) or real-world evidence (RWE) studies to be included. This bibliographic search was completed manually. A random-effect model meta-analysis was performed for any outcome reported in at least 2 studies. Subgroup analyses were performed on the type of GLP-1 RAs, type of comparator used and study design. Sensitivity analyses (i.e., leave-out sensitivity analyses and analyses restricted to the most adjusted effect estimate) were performed to test the robustness of the data. The strength of evidence was assessed using GRADE. This work has been performed in adherence with PRISMA statement. (PROSPERO Record ID: CRD420251024082). RESULTS: From 1148 potentially relevant references, 60 articles (46 RCTs, 13 RWE studies and 1 pharmacovigilance study, comprising 1,250,717 individuals) met our inclusion criteria. Different GLP-1 RAs were represented across the panel of studies, i.e., semaglutide, liraglutide, exenatide, dulaglutide, tirzepatide (dual agonist gastric inhibitory polypeptide [GIP]/GLP-1) and others. No effect on bone outcomes (i.e., bone mineral density [all sites] and fractures [all sites]) were observed when the meta-analytical models included the most adjusted effect size. Regarding muscle outcomes, a significant decrease of lean body mass/fat-free mass was consistently observed with GLP-1 RAs in the global model (k = 28, standardised mean difference [SMD] 0.52, 95% confidence interval [CI] -0.8; -0.23, I2 88%, p-value for heterogeneity <0.0001), which remained robust in all sensitivity analyses. Subgroup analyses showed that the effect was mainly driven by liraglutide and semaglutide, with a decrease in lean body mass/fat-free mass observed when GLP-1 RAs were compared with placebo. No publication bias was found. Regarding joint outcome, models revealed no significant change in The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain, physical function and stiffness. CONCLUSIONS: This meta-analysis is the first to investigate the effects of GLP-1 RAs on a large panel of musculoskeletal health outcomes. While no significant effects were observed on bone- or joint-related outcomes, GLP-1 RAs were associated with reductions in lean body mass/fat-free mass, although the certainty of evidence was low and these changes appeared largely related to weight loss. Whether these changes translate into clinically meaningful impairments in muscle function or physical performance remains uncertain. Further studies in this field, including those looking at muscle function, strength or performance and using multivariate models considering confounding are needed to better reinforce the models and final findings.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Beaudart C, Malréchauffé Y, van Heden S, et al. GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis. Drugs. 2026. PMID: 42730869. doi:10.1007/s40265-026-02365-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。